The Decipher genomic classifier obtained from biopsy samples was prognostic for distant metastases and prostate cancer-specific mortality.
A phase 3 study presented at the 2017 Genitourinary Cancers Symposium demonstrated the feasibility of conducting adjuvant trials.
Despite early failures, there may be a role for single-agent and combination immunotherapy for patients with prostate cancer.
A higher overall number of genetic alterations in cell-free circulating tumor DNA (ctDNA) were associated with worse treatment outcomes.
Investigators studied the effects of adding antiandrogen therapy to radiotherapy on cancer control and overall survival in men with prostate cancer recurrence after radical prostatectomy.
Clinicians May Want To Address Emotional Stress to Prevent Overtreatment of Localized Prostate CancerJanuary 30, 2017
Some men with low-risk prostate cancer may opt for more aggressive treatments due to emotional distress.
The implementation of recommendations opposing regular prostate cancer screening appear to have lowered treatment rates dramatically.
Results from a phase 3 trial comparing a 12-week dosing interval with the standard 4-week dosing interval of zoledronic acid to reduce the incidence of skeletal-related events and pain in patients with bone metastases.
This fact reviews how hormone therapy may be used to treat prostate cancer, treatment options for castration-resistant prostate cancer, and side effects of hormone therapy.
Patients on active surveillance with stable disease may be candidates for less intense surveillance
Although many men obtain a second opinion regarding their prostate cancer care options, they seldom deviate from the original course of action.
Magnetic resonance imaging and MRI-targeted biopsy can facilitate detection of clinically significant prostate disease.
Advanced prostate cancer is associated with substantial psychosocial morbidity; therefore, this study was conducted to evaluate whether mindfulness-based cognitive therapy reduces distress in this population.
Consensus statement presents guidelines for prostate magnetic resonance imaging (MRI) in patients with negative biopsy.
Role of Chemotherapy and Mechanisms of Resistance to Chemotherapy in Metastatic Castration-Resistant Prostate CancerNovember 18, 2016
[Clinical Medicine Insights: Oncology] This research examines the various mechanisms of resistance to chemotherapy in metastatic CRPC and the potential role of emerging regimens and agents in varying clinical phases of development.
Studies show better physical function and quality of life for cancer patients who do strength training or aerobic activity.
The impact of additional opinions on patient decision-making is limited.
Researchers report on their evaluation of the impact of the 2012 USPSTF recommendation on volumes of prostate biopsy and radical prostatectomy.
Researchers analyzed data from the NPCR of Sweden to determine whether more US men with prostate cancer would choose active surveillance if it were presented as a treatment option.
Growing evidence suggests a link between androgen deprivation therapy (ADT) and cognitive dysfunction, but whether it may contribute to the risk of dementia more broadly is unclear. In this study, researchers examined the association of ADT with subsequent development of dementia in patients with prostate cancer.
Radiotherapy administered postoperatively within 1 year of radical prostatectomy was associated with worse functional outcomes compared with radiotherapy administered 1 year or more after surgery.
Side effects experienced with extremely hypofractionated treatment for intermediate-risk prostate cancer were comparable to those of conventional radiation therapy at 2 years after treatment.
Prostate cancer survivors who maintain or begin recreational physical activity following cancer diagnosis report substantially higher quality of life than those who never exercise or stopped exercising after diagnosis.
Disease-specific mortality rates for men with prostate cancer are comparable for 3 treatment options: active surveillance, radical prostatectomy, and external-beam radiotherapy.
Despite that most patients with newly diagnosed prostate cancer receive high-quality care, a racial disparity exists, a recent study has shown.
The long-term use of androgen deprivation therapy (ADT) for up to 36 months does not appear to be associated with cognitive decline in patients with prostate cancer.
Following the USPSTF recommendation against routine PSA testing in all men, incidence rates of early stage prostate cancer in men 50 years and older declined substantially, according to a recent study.
Emotional distress is associated with an increased likelihood of opting for surgery among men with localized prostate cancer.
Race is not associated with the development of metastases in patients with nonmetastatic castration-resistant prostate cancer (CRPC), according to a recently published study.
Ethnicity influences patient decision to pursue active treatment and serial biopsies in active surveillance
- Cholesterol-Lowering Drugs May Prevent Breast Cancer Recurrence
- BBD Regimen Efficacious as First-line Therapy for Myeloma
- Idelalisib Increases Progression-Free Survival in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia
- Trends in Behaviors, Medical Practice Indicate Mortality From Melanoma Will Decline
- Pembrolizumab Active Against Rare Melanoma, Extends Survival in Bladder Cancer
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Nut Consumption Inversely Associated With Lung Cancer Risk
- Decipher Genomic Classifier Prognostic for Distant Prostate Metastasis
- GUCS 2017: Adjuvant Trials in Post-radical Prostatectomy Prostate Cancer Feasible
- Annual Screening of High-Risk Smokers Only More Cost-effective Than Current Methods
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Metronomic Chemotherapy: Improved Tumor Blood Supply Leads to Better Treatment
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|